XDx receives market clearance from the FDA for its AlloMap gene expression test for heart transplant recipients.
"AlloMap is a valuable tool in the management of heart transplant patients," said Howard Eisen, MD, professor and chief of cardiology at Drexel University College of Medicine in Philadelphia, PA. "As a simple blood test, AlloMap can be used on an ongoing basis to help to determine which heart transplant patients are the least likely to suffer from rejection, which is a key factor in the long-term well being and treatment of these patients."
XDx says AlloMap Testing assays the RNA levels of 11 rejection biomarker genes and nine control genes. AlloMap Testing was clinically validated using data from 9 leading heart transplant centers participating in the company's Cardiac Allograft Rejection Gene Expression Observational (CARGO) study. AlloMap test has been available since January 2005 as a Laboratory Developed Test (LDT) performed in the XDx Clinical Laboratory Improvement Amendments (CLIA) certified laboratory, and has been ordered at more than 50 US transplant centers.
The test may be used for stable patients aged 15 years or older at any time after the second month post-transplant. XDx says the AlloMap test is currently only performed at the company's Reference Laboratory in order to maintain tight control of the testing processes.
Contact: Web site: www.xdx.com
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 1, 2008|
|Previous Article:||CDC DVD professional education video available from HRSA at no charge.|
|Next Article:||CMS issues decision to approve SynCardia's CardioWest artificial heart for highest reimbursement ever.|